吉妥珠单抗奥唑米星治疗后迟发性肝静脉闭塞病：去纤苷成功治疗 - Suppr | 超能文献

Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide.

作者信息

Saviola Alessia, Luppi Mario, Potenza Leonardo, Morselli Monica, Ferrari Angela, Riva Giovanni, Torelli Giuseppe

出版信息

Br J Haematol. 2003 Nov;123(4):752-3. doi: 10.1046/j.1365-2141.2003.04667.x.

DOI:10.1046/j.1365-2141.2003.04667.x

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Late occurrence of hepatic veno-occlusive disease following gemtuzumab ozogamicin: successful treatment with defibrotide.吉妥珠单抗奥唑米星治疗后迟发性肝静脉闭塞病：去纤苷成功治疗

Br J Haematol. 2003 Nov;123(4):752-3. doi: 10.1046/j.1365-2141.2003.04667.x.

2

Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis.

Med Oncol. 2003;20(4):379-84. doi: 10.1385/MO:20:4:379.

3

Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).抗CD33治疗（吉妥珠单抗奥唑米星）后的肝静脉闭塞病

Br J Haematol. 2002 Mar;116(4):924. doi: 10.1046/j.0007-1048.2002.03346.x.

4

Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure.在接受吉妥珠单抗奥唑米星治疗后进行干细胞移植时，使用去纤苷进行预防可预防静脉闭塞性疾病。

Blood. 2004 Mar 1;103(5):1968. doi: 10.1182/blood-2003-10-3612.

5

Gemtuzumab ozogamicin (MylotargTM) is infrequently associated with sinusoidal obstructive syndrome/veno-occlusive disease.吉妥珠单抗奥唑米星（麦罗塔TM）与窦性阻塞综合征/静脉闭塞性疾病的关联并不常见。

Ann Oncol. 2004 Aug;15(8):1231-6. doi: 10.1093/annonc/mdh324.

6

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.吉妥珠单抗奥唑米星：急性髓系白血病患者的希望与挑战

Expert Rev Anticancer Ther. 2002 Dec;2(6):630-40. doi: 10.1586/14737140.2.6.630.

7

Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease.异基因干细胞移植中预防性使用去纤苷：静脉闭塞性疾病的发病率极低且死亡率为零。

Bone Marrow Transplant. 2007 Jul;40(1):79-82. doi: 10.1038/sj.bmt.1705696. Epub 2007 May 14.

8

Sinusoidal Obstruction Syndrome During Chemotherapy of Pediatric Cancers and its Successful Management With Defibrotide.儿童癌症化疗期间的窦性阻塞综合征及其用去纤苷的成功治疗

J Pediatr Hematol Oncol. 2017 Oct;39(7):e373-e376. doi: 10.1097/MPH.0000000000000958.

9

BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.BCSH/BSBMT 指南：造血干细胞移植后静脉闭塞病（窦状隙阻塞综合征）的诊断和治疗。

Br J Haematol. 2013 Nov;163(4):444-57. doi: 10.1111/bjh.12558. Epub 2013 Sep 17.

10

Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation.先前使用吉妥珠单抗奥佐米星和异基因造血干细胞移植后静脉闭塞性疾病的风险。

Bone Marrow Transplant. 2010 Jan;45(1):165-70. doi: 10.1038/bmt.2009.153. Epub 2009 Jul 6.

引用本文的文献

1

Thrombotic microangiopathy in haematopoietic cell transplantation: an update.造血细胞移植中的血栓性微血管病：最新进展。

Mediterr J Hematol Infect Dis. 2010;2(3):e2010033. doi: 10.4084/MJHID.2010.033. Epub 2010 Nov 3.

2

What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?吉妥珠单抗奥佐米星在急性髓系白血病治疗中起什么作用？

Curr Hematol Malig Rep. 2007 May;2(2):104-10. doi: 10.1007/s11899-007-0015-1.

3

Thrombotic microangiopathy in haematopoietic stem cell transplantation: diagnosis and treatment.造血干细胞移植中的血栓性微血管病：诊断与治疗

Drugs. 2009;69(2):183-98. doi: 10.2165/00003495-200969020-00004.